Topigen/Novagali Ocular, Respiratory Therapies Under Development
This article was originally published in The Pink Sheet Daily
Executive SummaryCross-licensing deal gives Novagali access to Topigen’s RNA-targeting platform for eye diseases, and Topigen access to Novagali’s Novasorb technology for respiratory conditions.
You may also be interested in...
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.